首页> 美国卫生研究院文献>Genes >Transgenic Tobacco Expressing the TAT-Helicokinin I-CpTI Fusion Protein Show Increased Resistance and Toxicity to Helicoverpa armigera (Lepidoptera: Noctuidae)
【2h】

Transgenic Tobacco Expressing the TAT-Helicokinin I-CpTI Fusion Protein Show Increased Resistance and Toxicity to Helicoverpa armigera (Lepidoptera: Noctuidae)

机译:表达TAT-Helkinkinin I-CpTI融合蛋白的转基因烟草显示对棉铃虫的抗性和毒性增加(鳞翅目:夜蛾科)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Insect kinins were shown to have diuretic activity, inhibit weight gain, and have antifeedant activity in insects. In order to study the potential of the TAT-fusion approach to deliver diuretic peptides per os to pest insects, the HezK I peptide from Helicoverpa zea, as a representative of the kinin family, was selected. The fusion gene TAT-HezK I was designed and was used to transform tobacco plants. As a means to further improve the stability of TAT-HezK I, a fusion protein incorporating HezK I, transactivator of transcription (TAT), and the cowpea trypsin inhibitor (CpTI) was also designed. Finally, the toxicity of the different tobacco transgenic strains toward Helicoverpa armigera was compared. The results demonstrated that TAT-HezK I had high toxicity against insects via transgenic expression of the peptide in planta and intake through larval feeding. The toxicity of the fusion TAT-HezK I and CpTI was higher than the CpTI single gene in transgenic tobacco, and the fusion TAT-HezK I and CpTI further enhanced the stability and bioavailability of agents in oral administration. Our research helps in targeting new genes for improving herbivore tolerance in transgenic plant breeding.
机译:已证明昆虫激肽在昆虫中具有利尿作用,抑制体重增加并具有拒食活性。为了研究TAT融合方法将os利尿肽递给害虫的潜力,选择了Helicoverpa zea的HezK I肽作为激肽家族的代表。设计了融合基因TAT-HezK I,并将其用于转化烟草植物。作为进一步提高TAT-HezK I稳定性的方法,还设计了融合了HezK I,转录反式激活子(TAT)和the豆胰蛋白酶抑制剂(CpTI)的融合蛋白。最后,比较了不同烟草转基因菌株对棉铃虫的毒性。结果表明,TAT-HezK I通过肽在植物中的转基因表达和通过幼虫摄食而对昆虫具有高毒性。 TAT-HezK I和CpTI融合体在转基因烟草中的毒性高于CpTI单基因,TAT-HezK I和CpTI融合体进一步增强了口服制剂的稳定性和生物利用度。我们的研究有助于针对新基因,以提高转基因植物育种中的草食动物耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号